National Cancer Institute TitleKeywordsActivity CodeFOALOI Due DateApplication Due Date (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environmentsprevention, controlR01, R03, R21NOT-CA-25-0121/8/2028 (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Researchbiomarkers, lifestyle interventions, prevention, interception, diet, physical activityR01, R03, R21NOT-CA-24-0741/8/2027 Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)Exploratory, Early-stage, cancer control, novel, ESIR21PA-25-2535/17/20256/16/2025 Clinical Characterization of Cancer Therapy - induced Adverse Sequelae and Mechanism - based Interventional Strategies (R01 Clinical Trial Optional)collaborative, therapies, basic, translational, clinical, biomarkers, R01PAR-25-1459/5/202510/5/2025 Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)Communication, social media, online tools, health information, publicR21PA-25-2956/16/2025 (NOSI): NCI's Interest in Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatmentmultidisciplinary, collaborationNOT-CA-25-0071/8/2028 (NOSI): Survivorship Research for People Living with Advanced and Metastatic Cancerspalliative, quality-of-life, psychosocialNOT-CA-25-0241/8/2028 (NOSI): Communication and Decision-Making in a Complex and Dynamic Cancer Treatment Environmentenvironment, patient-providerNOT-CA-25-0069/8/2028 (NOSI): Mechanisms Driving Obesity and Prostate Cancer Riskprostate, risk, preventionR00, R01, R21, K99NOT-CA-25-0021/8/2028 (NOSI): Research on rare cancers across the cancer control continuumtreatment, diagnosis, epidemiologyR01, R03, R21, R34, U34, P01NOT-CA-25-0101/8/2028 Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)Novel, Technology, Acceleration, Clinical TrialR01RFA-CA-25-0059/3/202510/3/2025 Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)molecular, biomarkers, therapies, clinical UH2, UH3PAR-25-0746/11/2025 Co-infection and Cancer (R01 Clinical Trial Not Allowed)infectious diseases, viruses, bacteria, HIV, HPVR01PAR-25-08210/5/2025 The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)Systems-level, mechanisms of responses. Therapy, novel, data, collaborativeU01PAR-25-1305/21/20256/20/2025 Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)Dissemination, implementationR21PAR-25-1435/17/20256/16/2025 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)dissemination, implementation, evidence-based interventions, publicR01PAR-25-1449/5/202510/5/2025 Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)dissemination, implementation, evidence-based interventionsR03PAR-25-2335/17/20256/16/2025 Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)Nanotechnology, Brain Disorders, Biomedical Systems, BiomarkersR01PAR-25-10611/3/2025 NCMRR Early Career Research Award (R03 Clinical Trial Optional)Biomedical Informatics, Cancer Informatics, Health Data Management, Cancer ResearchR03PAR-25-1246/18/0275 Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)Pediatric, birth defects, data analysis, geneticR03PAR-25-1096/18/0275 Health disparitiesR01PAR-25-24010/5/2025 Health disparitiesPAR-25-2416/18/0275 Can’t find what you’re looking for? Please contact researchdevelopment@cancer.ufl.edu for assistance in finding additional funding opportunities.
